Divis Laboratories receives EIR for Visakhapatnam unit

18 Nov 2017 Evaluate

Divis Laboratories has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its Unit-II, located at Visakhapatnam, Andhra Pradesh, as closure of audit by USFDA.

Earlier in September, the company's Unit-II was inspected by USFDA wherein a Form-483 was issued with 6 observations. 

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Divis Lab Share Price

6345.90 -48.75 (-0.76%)
01-Jan-2026 13:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.00
Dr. Reddys Lab 1251.00
Cipla 1501.55
Zydus Lifesciences 912.50
Lupin 2101.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×